News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
37–55
Matches
55
Sources here
12
Companies here
1
Search results Stored financial headlines

Active search

55 matching headlines

Ticker or company: NURIMain company stories
Clear

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

Investing.com Earnings Main company 🇺🇸 United States

Nurix Therapeutics chief legal officer sells $89,953 in stock

Christine Ring, Chief Legal Officer at Nurix Therapeutics, sold $89,953 worth of stock on July 30, 2026, to cover tax withholding obligations from RSU vesting, not through discretionary trades. These sales occurred as the NRIX stock trades near its 52-week high after a significant …

NRIX main company
Sharemaestro market context Trend signal active 52 weeks +166.8% · Next-week setup positive 56.4% NRIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Analyst action Main company 🇺🇸 United States

Nurix Therapeutics, Inc. $NRIX is Redmile Group LLC's 5th Largest Position

Redmile Group LLC slightly reduced its stake in Nurix Therapeutics (NASDAQ:NRIX) by 4.5% during Q1, though it remains their 5th largest holding, valued at $119.86 million. Other major investors like Vanguard Group, General Atlantic, and Morgan Stanley significantly increased their positions in the company. …

NRIX main company
Sharemaestro market context Trend signal active 52 weeks +166.8% · Next-week setup positive 56.4% NRIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Nurix Therapeutics Inc (NRIX) Financial Health: Profitability & Balance Sheet Analysis

Nurix Therapeutics Inc (NRIX) currently has a financial score of 6.71, ranking 225 out of 385 in the Biotechnology & Medical Research industry, indicating a weak financial status and average operating efficiency. The company's latest quarterly revenue was $9.04 million, a significant year-over-year decrease …

NRIX main company
Sharemaestro market context Trend signal active 52 weeks +166.8% · Next-week setup positive 56.4% NRIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Moomoo Analyst action Main company 🇺🇸 United States

Morgan Stanley Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Raises Target Price to $38

Morgan Stanley has reiterated its Buy rating on Nurix Therapeutics (NRIX.US) and increased its price target for the company's stock to $38. This indicates continued confidence in the pharmaceutical company's future performance and growth prospects from the investment bank.

NRIX main company
Sharemaestro market context Trend signal active 52 weeks +166.8% · Next-week setup positive 56.4% NRIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
GuruFocus Analyst action Main company 🇺🇸 United States

NRIX Maintained by Morgan Stanley -- Price Target Raised to $38

Morgan Stanley has maintained its "Overweight" rating for Nurix Therapeutics (NRIX) and increased its price target from $36.00 to $38.00, signaling a positive outlook despite the company's current financial challenges. However, GuruFocus indicates that NRIX is significantly overvalued by 266.9% based on its GF …

NRIX main company
Sharemaestro market context Trend signal active 52 weeks +166.8% · Next-week setup positive 56.4% NRIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

NRIX|Nurix Therapeutics Inc|Price:22.987|Chg%:-0.443

This article provides a comprehensive stock analysis of Nurix Therapeutics Inc (NRIX), highlighting its strong fundamentals, high growth potential, and relatively fair valuation within the Biotechnology & Medical Research industry. The company's stock is rated as "Buy" by multiple analysts, with a highest price …

NRIX main company
Sharemaestro market context Trend signal active 52 weeks +166.8% · Next-week setup positive 56.4% NRIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Nurix Therapeutics Inc (NRIX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

The article provides a revenue breakdown for Nurix Therapeutics Inc (NRIX), discussing its business segments, regional revenue, and profit contribution. However, it explicitly states that the relevant financial data has not yet been disclosed by the company, meaning specific details on these breakdowns are …

NRIX main company
Sharemaestro market context Trend signal active 52 weeks +166.8% · Next-week setup positive 56.4% NRIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Market update Main company 🇺🇸 United States

Nurix Therapeutics Inc (NRIX) Institutional Confidence

Nurix Therapeutics Inc (NRIX) has a strong institutional confidence score of 10.00, placing it first in the Biotechnology & Medical Research industry. Institutional shareholding has increased by 38.35% quarter-over-quarter, with the largest holder being Bill Nygren | OAKMX despite a decrease in their holdings. …

NRIX main company
Sharemaestro market context Trend signal active 52 weeks +166.8% · Next-week setup positive 56.4% NRIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Market update Main company 🇺🇸 United States

Nurix Therapeutics Inc (NRIX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Nurix Therapeutics Inc (NRIX), listing its major shareholders and their respective proportions. It also outlines institutional holdings over several quarters, showing changes in the number of institutions and shares held. Additionally, the report identifies the breakdown of …

NRIX main company
Sharemaestro market context Trend signal active 52 weeks +166.8% · Next-week setup positive 56.4% NRIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Yahoo! Finance Canada Earnings Main company 🇺🇸 United States

Nurix Therapeutics, Inc. (NRIX) Stock Price, News, Quote & History

This article provides a detailed financial overview of Nurix Therapeutics, Inc. (NRIX), including its stock price, historical data, and key metrics. It highlights the company's focus on developing small molecule and antibody therapies for various diseases and its strategic collaborations. The report also includes …

NRIX main company
Sharemaestro market context Trend signal active 52 weeks +166.8% · Next-week setup positive 56.4% NRIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stocktwits Earnings Main company 🇺🇸 United States

NRIX: Nurix Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas

This article provides the latest stock information for Nurix Therapeutics Inc. (NRIX), including its current stock price, pre-market change, market capitalization, volume, and various financial metrics like P/E ratio and EPS. It also lists recent news articles related to NRIX and trending stock discussions.

NRIX main company
Sharemaestro market context Trend signal active 52 weeks +166.8% · Next-week setup positive 56.4% NRIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Moomoo Analyst action Main company 🇺🇸 United States

UBS Lifts Nurix Therapeutics Price Target to $31 From $23, Maintains Buy Rating

UBS has increased its price target for Nurix Therapeutics (NRIX) shares to $31 from $23, while maintaining a Buy rating on the stock. This adjustment reflects a more optimistic outlook by the financial institution on the company's future performance.

NRIX main company
Sharemaestro market context Trend signal active 52 weeks +166.8% · Next-week setup positive 56.4% NRIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Investing.com Deals and strategy Main company 🇺🇸 United States

Nurix closes $700m Roche collaboration for bexobrutideg

Nurix Therapeutics Inc. has finalized a collaboration agreement with Roche for the co-development and co-commercialization of bexobrutideg, an investigational therapy. Nurix will receive an upfront payment of $700 million and is eligible for up to $2.3 billion in total payments through milestones. The companies …

NRIX main company
Sharemaestro market context Trend signal active 52 weeks +166.8% · Next-week setup positive 56.4% NRIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
The Manila Times Deals and strategy Main company 🇺🇸 United States

Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

Nurix Therapeutics announced the closing of its global collaboration agreement with Roche to co-develop and co-commercialize bexobrutideg, a potential best-in-class BTK degrader. This follows the expiration of the Hart-Scott-Rodino Antitrust Improvements Act waiting period. Nurix will receive an upfront payment of $700 million and …

NRIX main company
Sharemaestro market context Trend signal active 52 weeks +166.8% · Next-week setup positive 56.4% NRIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Deals and strategy Main company 🇺🇸 United States

Nurix to Receive $700M Upfront in Roche Bexobrutideg Deal

Nurix Therapeutics announced the closing of its global collaboration with Roche to co-develop and co-commercialize bexobrutideg, a BTK degrader. Nurix will receive an upfront payment of $700 million and is eligible for up to $2.3 billion in potential development, regulatory, and sales milestones. Development …

NRIX main company
Sharemaestro market context Trend signal active 52 weeks +166.8% · Next-week setup positive 56.4% NRIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Traders Daily Market update Main company 🇺🇸 United States

Precision Trading with Nurix Therapeutics Inc. (NRIX) Risk Zones

This article provides an in-depth analysis of Nurix Therapeutics Inc. (NRIX), highlighting strong sentiment across all horizons and a mid-channel oscillation pattern. It outlines institutional trading strategies, including long and short setups, and offers multi-timeframe signal analysis with key support and resistance levels. The …

NRIX main company
Sharemaestro market context Trend signal active 52 weeks +166.8% · Next-week setup positive 56.4% NRIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Webull Earnings Main company 🇺🇸 United States

How Investors May Respond To Nurix Therapeutics (NRIX) Deepening Losses And Sharply Lower Collaboration Revenue

Nurix Therapeutics (NRIX) reported widening losses and sharply lower collaboration revenue for its recent quarter and half-year, with a net loss of US$89.54 million and US$176.71 million, respectively. The company's investment narrative relies on its protein degradation platform and the recent Roche partnership, which …

NRIX main company
Sharemaestro market context Trend signal active 52 weeks +166.8% · Next-week setup positive 56.4% NRIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MSN Analyst action Main company 🇺🇸 United States

Oppenheimer Maintains Nurix Therapeutics (NRIX) Outperform Recommendation

Oppenheimer has reiterated its Outperform rating for Nurix Therapeutics (NRIX). The firm's continued positive outlook on NRIX suggests confidence in the company's future performance. This maintenance of an Outperform recommendation may influence investor perception and stock performance.

NRIX main company
Sharemaestro market context Trend signal active 52 weeks +166.8% · Next-week setup positive 56.4% NRIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Analyst action Main company 🇺🇸 United States

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Average Rating of "Moderate Buy" by Brokerages

Nurix Therapeutics, Inc. (NASDAQ:NRIX) has received an average rating of "Moderate Buy" from fourteen brokerages, with an average 12-month price target of $34.08. Several analysts have recently raised their price targets, despite the company missing its latest quarterly earnings and revenue expectations. Insiders have …

NRIX main company
Sharemaestro market context Trend signal active 52 weeks +166.8% · Next-week setup positive 56.4% NRIX stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context